{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Newly+Diagnosed+Glioblastoma+Multiforme&page=12",
    "query": {
      "condition": "Newly Diagnosed Glioblastoma Multiforme",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 338,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Newly+Diagnosed+Glioblastoma+Multiforme&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Newly+Diagnosed+Glioblastoma+Multiforme&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T04:48:09.272Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05664243",
      "title": "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Autologous genetically modified gamma-delta T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Allogeneic genetically modified gamma-delta T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "In8bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-09-08",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Louisville, Kentucky + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05664243"
    },
    {
      "nct_id": "NCT00813943",
      "title": "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Cilengitide (2-times weekly)",
          "type": "DRUG"
        },
        {
          "name": "cilengitide (5-times weekly)",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2009-03",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813943"
    },
    {
      "nct_id": "NCT06973096",
      "title": "CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "CART-EGFR-IL13Ra2 cells",
          "type": "DRUG"
        },
        {
          "name": "Rituximab or Rituximab biosimilar",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine + Cyclophosphamide combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2025-07-18",
      "completion_date": "2042-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06973096"
    },
    {
      "nct_id": "NCT05739942",
      "title": "Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Newly Diagnosed and Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "[177Lu]Lu-NeoB",
          "type": "DRUG"
        },
        {
          "name": "[68Ga]Ga-NeoB",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 42,
      "start_date": "2024-05-15",
      "completion_date": "2027-08-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05739942"
    },
    {
      "nct_id": "NCT01977677",
      "title": "Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Ependymoblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Medulloblastoma",
        "Adult Mixed Glioma",
        "Adult Oligodendroglial Tumors",
        "Adult Pineoblastoma",
        "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)"
      ],
      "interventions": [
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Lawrence Recht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-11",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-23",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01977677"
    },
    {
      "nct_id": "NCT02805179",
      "title": "A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "High Dose Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2016-09-22",
      "completion_date": "2020-11-18",
      "has_results": true,
      "last_update_posted_date": "2021-04-15",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02805179"
    },
    {
      "nct_id": "NCT03463265",
      "title": "Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "nab-sirolimus",
          "type": "DRUG"
        },
        {
          "name": "nab-sirolimus + temozolomide",
          "type": "DRUG"
        },
        {
          "name": "nab-sirolimus + bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "nab-sirolimus + lomustine",
          "type": "DRUG"
        },
        {
          "name": "nab-sirolimus + marizomib (MRZ)",
          "type": "DRUG"
        },
        {
          "name": "nab-sirolimus + temozolomide + radiotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aadi Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2018-08-01",
      "completion_date": "2022-08-26",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 3,
      "location_summary": "Fullerton, California • Newport Beach, California • Santa Monica, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03463265"
    },
    {
      "nct_id": "NCT03506139",
      "title": "Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "External beam radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "John M. Buatti",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-05-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-09-09",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03506139"
    },
    {
      "nct_id": "NCT00262730",
      "title": "Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 97,
      "start_date": "2006-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2019-06-12",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262730"
    },
    {
      "nct_id": "NCT03452930",
      "title": "Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma",
        "MGMT-Unmethylated Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Tinostamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-08-13",
      "completion_date": "2024-06-05",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-10-14T04:48:09.272Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452930"
    }
  ]
}